OncLiveDr. Levine on Immunotherapy for Endometrial CancerOncLiveDouglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses immunotherapy for patients with… Continue reading
OncLiveExpert Highlights Immunotherapy Potential in Ovarian CancerOncLiveIn an interview with OncLive at the 2017 State of the Science SummitTM on Treatment Options in Ovarian Cancer, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Cen… Continue reading
OncLiveExpert Highlights Immunotherapy Potential in Ovarian CancerOncLiveIn an interview with OncLive at the 2017 State of the Science SummitTM on Treatment Options in Ovarian Cancer, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Cen… Continue reading
OncLiveExpert Highlights Immunotherapy Potential in Ovarian CancerOncLiveIn an interview with OncLive at the 2017 State of the Science SummitTM on Treatment Options in Ovarian Cancer, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Cen… Continue reading
|
Man beats cancer with immunotherapy and cycling
New Haven Register (AP) — Doctors told South Meriden resident Daniel Santomero he had 18 months to live in August 2015 when he was diagnosed with Stage-4 head and neck cancer. Two years later, he has beaten the odds thanks to experimental immunotherapy treatment. |
|
Man beats cancer with immunotherapy and cycling
CT Post (AP) — Doctors told South Meriden resident Daniel Santomero he had 18 months to live in August 2015 when he was diagnosed with Stage-4 head and neck cancer. Two years later, he has beaten the odds thanks to experimental immunotherapy treatment. |
OncLive |
NSCLC Immunotherapy: Transformation of Upfront Therapy
OncLive Everett Vokes, MD: Hello, and thank you for joining this OncLive® Peer Exchange® titled “Immuno-Oncology in Advanced Lung Cancer.” We continue to see extraordinary progress in the treatment of advanced non–small cell lung cancer, with … |
Boston Business Journal |
Gene therapy firm Dimension would keep Cambridge office under latest buyout offer
Boston Business Journal A bidding war between California-based Ultragenyx Pharmaceutical against Regenxbio of Maryland could determine the fate of Dimension’s headquarters and employees. Subscribe to get the full story. Already a subscriber? Sign in. Subscribe to get the |